Luca MD - VectivBio Holding CEO Founder
| VECTDelisted Stock | USD 16.85 0.00 0.00% |
Insider
Luca MD is CEO Founder of VectivBio Holding AG
| Age | 54 |
| Phone | 41 61 551 30 3 |
| Web | https://vectivbio.com |
VectivBio Holding Management Efficiency
The company has return on total asset (ROA) of (0.2587) % which means that it has lost $0.2587 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5692) %, meaning that it created substantial loss on money invested by shareholders. VectivBio Holding's management efficiency ratios could be used to measure how well VectivBio Holding manages its routine affairs as well as how well it operates its assets and liabilities.VectivBio Holding AG currently holds 10.46 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. VectivBio Holding has a current ratio of 4.6, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about VectivBio Holding's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Nandan BS | Immix Biopharma | 62 | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| MBA MD | Immix Biopharma | 49 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Donald Picker | Cns Pharmaceuticals | 78 | |
| David Dornan | Elevation Oncology | 46 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| RPh PharmD | Elevation Oncology | 40 | |
| Peter Facchini | Enveric Biosciences | 60 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Gabriel BA | Immix Biopharma | 37 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| DSc MSE | Immix Biopharma | 75 | |
| MBA IV | Enveric Biosciences | 68 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
Management Performance
| Return On Equity | -0.57 | |||
| Return On Asset | -0.26 |
VectivBio Holding Leadership Team
Elected by the shareholders, the VectivBio Holding's board of directors comprises two types of representatives: VectivBio Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VectivBio. The board's role is to monitor VectivBio Holding's management team and ensure that shareholders' interests are well served. VectivBio Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VectivBio Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Luca MD, CEO Founder | ||
| Claudia DAugusta, Chief Officer | ||
| Kevin MBA, Chief Officer | ||
| Christian MD, Chief Officer | ||
| Sarah Holland, Chief Officer | ||
| Alain Bernard, Chief Officer | ||
| Patrick Malloy, VP Communications | ||
| Scott Applebaum, Chief Sec | ||
| Michael Steininger, VP HR | ||
| Omar MD, Chief Officer |
VectivBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VectivBio Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.57 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (2.95) % | |||
| Current Valuation | 846.2 M | |||
| Shares Outstanding | 62.81 M | |||
| Shares Owned By Insiders | 4.50 % | |||
| Shares Owned By Institutions | 83.80 % | |||
| Number Of Shares Shorted | 77.6 K | |||
| Price To Book | 3.62 X | |||
| Price To Sales | 21.08 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in VectivBio Stock
If you are still planning to invest in VectivBio Holding check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VectivBio Holding's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |